NEW YORK – Non-invasive algorithmic diagnostics company Fibronostics announced Monday it has raised $8 million in a Series A financing round.
The round was led by Singapore-based private investment firm AT Capital and Elev8.vc, a deep-tech venture capital fund. Fibronostics said it has plans to move into new markets and grow its product line and will use the funding to accelerate US commercialization of its Liverfast test, as well as to expand its software platform with new products targeting other diseases, including kidney and lung diseases and COVID-19.
The Liverfast test diagnoses liver disease from a blood draw, using artificial intelligence technology and biomarkers to stage organ lesions. It also has a cloud platform to integrate with healthcare providers, Singapore-based Fibronostics said. Liverfast was recently granted a CPT code by the American Medical Association, setting a pathway for reimbursement in the US.